Genfit (GNFTF) to Release Earnings on Thursday

Genfit (OTCMKTS:GNFTF) will likely be announcing its results after the market closes on Thursday, April 2nd. Analysts expect the company to announce earnings of ($0.0352) per share and revenue of $42.1650 million for the quarter.

Genfit Stock Performance

Shares of GNFTF stock opened at $10.43 on Tuesday. Genfit has a fifty-two week low of $4.14 and a fifty-two week high of $10.88. The business has a fifty day simple moving average of $8.73 and a 200-day simple moving average of $5.87.

Genfit Company Profile

Genfit is a clinical‐stage biopharmaceutical company headquartered in Lille, France, specializing in the development of innovative therapies and diagnostics for liver and metabolic diseases. The company’s research and development efforts are primarily focused on non‐alcoholic steatohepatitis (NASH), a progressive liver disorder with significant unmet medical needs. Genfit’s lead therapeutic candidate, elafibranor, is designed to target key pathways involved in inflammation, fibrosis and lipid metabolism, positioning it as a potential treatment for patients with NASH and associated metabolic complications.

In addition to its therapeutic pipeline, Genfit has established a diagnostic arm centered on NIS4®, a proprietary blood‐based test that leverages transcriptomic biomarkers to enable earlier and more accurate detection of liver fibrosis in patients at risk for NASH.